chronic
obstruct
pulmonari
diseas
copd
character
persist
airflow
limit
usual
associ
increas
inflammatori
bronchial
biopsi
stabl
mild
copd
patient
show
increas
level
inflammatori
cell
compar
healthi
nonsmok
among
cell
tlymphocyt
neutrophil
macrophag
sever
copd
decreas
total
number
inflammatori
cell
preval
inflammatori
cell
phagocyt
proteolyt
activ
neutrophil
macrophag
acut
exacerb
copd
caus
worsen
lung
function
last
mani
week
acceler
rate
lung
function
viral
bacteri
infect
respiratori
system
major
caus
copd
exacerb
microbiolog
examin
sputum
copd
patient
hospit
exacerb
show
infect
mostli
associ
bacteri
pathogen
sputum
follow
combin
bacteria
virus
sputum
anoth
follow
copd
patient
year
observ
high
rate
exacerb
one
subgroup
caus
bacteria
virus
bacteria
virus
undefin
mani
investig
observ
chang
inflammatori
respons
copd
patient
acut
exacerb
show
gener
increas
inflammatori
exacerb
associ
increas
neutrophil
tlymphocyt
case
virus
bacteria
may
caus
acut
exacerb
copd
altern
may
amplifi
chronic
inflamm
stabl
aforement
data
howev
come
separ
experiment
set
use
differ
methodolog
approach
render
difficult
direct
comparison
load
lung
copd
patient
relat
immun
host
respons
date
data
avail
dynam
mechan
bacteria
virus
colon
lung
precis
relationship
event
diseas
progress
stabl
exacerb
copd
review
focus
present
knowledg
regard
microbiom
load
either
bacteria
virus
stabl
exacerb
copd
deal
depth
immun
respons
relat
infect
sinc
review
alreadi
publish
topic
also
vivo
data
avail
focu
instead
dynam
event
involv
copd
progress
touch
futur
prospect
therapeut
strategi
pathogen
bacteria
identifi
use
cultur
techniqu
patient
stabl
limit
cultur
techniqu
howev
possibl
contamin
upper
airway
moreov
bacteri
speci
cultur
current
mani
remain
speci
difficult
develop
nonculturebas
techniqu
quantit
polymeras
chain
reaction
qpcr
improv
capac
detect
bacteria
shown
lung
mix
bacteri
speci
compos
lung
microbiom
contribut
diseas
state
chronic
respiratori
lower
airway
copd
patient
colon
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
patient
sever
diseas
pseudomona
aeruginosa
figur
studi
stablest
copd
observ
direct
correl
airway
inflamm
bacteri
load
exampl
advent
nonculturebas
techniqu
hill
et
perform
sputum
cultur
stabl
copd
patient
normal
blood
level
sever
defici
idiopath
bronchiectasi
observ
bacteri
load
correl
airway
inflamm
patient
stabl
chronic
garcha
et
studi
sputum
sampl
patient
qpcr
observ
stabl
copd
higher
bacteri
load
correl
sever
bronchial
obstruct
higher
dosag
inhal
corticosteroid
higher
creactiv
protein
crp
level
recent
barker
et
studi
sputum
sampl
patient
stabl
copd
pair
sputum
subject
stabl
exacerb
diseas
use
qpcr
observ
major
patient
stabl
state
pathogen
bacteria
airway
detect
bacteria
mean
nonculturebas
techniqu
qpcr
also
associ
increas
sputum
interleukin
il
tumor
necrosi
factor
decreas
chemokin
cc
motif
ligand
stabl
state
strongest
relationship
bacteri
load
inflamm
symptom
observ
h
influenza
whether
codetect
bacteria
sole
pathogen
singh
et
analyz
sputum
stabl
copd
patient
qpcr
observ
direct
correl
load
h
influenza
pneumonia
catarrhali
airway
inflamm
plasmat
fibrinogen
erbdownward
et
analyz
bronchoalveolar
lavag
bal
fluid
three
never
smoker
seven
healthi
smoker
four
copd
patient
eight
sampl
obtain
six
patient
undergo
lung
transplant
copd
signific
bacteri
load
found
subject
without
signific
differ
group
smoker
normal
lung
function
author
found
lower
divers
lung
microbiota
specul
rel
reduct
divers
could
persist
could
either
effect
lung
inflamm
part
caus
diseas
onset
molecular
aspect
dynam
modif
bacteri
load
bacteri
type
relat
patient
immun
respons
need
studi
hypothes
appear
new
strain
foreign
microb
initi
cycl
infect
inflammatori
respons
dysfunct
remodel
drive
progress
sze
et
analyz
sampl
surgic
lung
resect
lung
transplant
donor
smoker
eight
sampl
nonsmok
eight
sampl
copd
patient
eight
sampl
cystic
fibrosi
patient
eight
sampl
show
differ
bacteri
commun
copd
lung
tissu
compar
group
actinobacteria
abund
smoker
group
lactobacillu
consist
present
copd
global
initi
chronic
obstruct
lung
diseas
gold
group
cystic
fibrosi
copd
group
burkholderia
genu
repres
bacteri
commun
increas
presenc
lactobacillu
lung
could
relat
inflammatori
state
associ
format
tertiari
lymphoid
follicl
develop
near
small
lactobacillu
could
either
target
inflamm
altern
could
act
immun
modul
aid
inflammatori
respons
studi
author
show
sever
copd
group
shift
rel
abund
bacteri
popul
without
one
becom
domin
rel
abund
increas
divers
bacteri
popul
copd
observ
pragman
et
studi
bal
sampl
patient
moderatetosever
copd
ten
control
wu
et
analyz
sputum
ten
copd
control
subject
et
studi
nonculturebas
techniqu
bronchial
microbiom
sputum
stabl
copd
patient
observ
patient
sever
diseas
proteobacteria
phylum
overrepres
togeth
diminut
bacteria
belong
firmicut
phylum
author
specul
chang
lung
microbiom
sever
copd
patient
could
due
either
alter
airway
typic
sever
diseas
patient
repeat
use
antibiot
alter
microbiom
composit
observ
may
induc
lung
inflamm
contribut
worsen
recent
sze
et
examin
lung
sampl
five
copd
gold
stage
subject
confirm
reduct
microbi
divers
rel
increas
proteobacteria
actinobacteria
reduct
firmicut
bacteroidet
phyla
author
moreov
report
signific
associ
alter
microbiom
extent
emphysema
remodel
bronchi
alveoli
infiltr
tcell
sze
et
al
hypothes
increas
abund
proteobacteria
actinobacteria
copd
gold
stage
airway
could
stimul
intens
lung
find
contrast
discrep
could
due
small
number
patient
analyz
studi
differ
studi
design
tabl
furthermor
studi
erbdownward
et
base
sampl
obtain
bal
bronchial
brush
studi
sze
et
sampl
obtain
lung
tissu
render
find
less
directli
compar
limit
studi
sze
et
absenc
moder
sever
copd
group
gold
stage
leav
open
question
whether
emerg
lactobacillu
burkholderia
lung
gradual
progress
sudden
occurr
pragman
et
studi
bal
sampl
et
analyz
sputum
sampl
fact
influenc
find
heterogen
copd
popul
patient
predomin
emphysema
other
chronic
bronchiti
preval
moreov
differ
drug
use
treat
diseas
copd
patient
could
alter
lung
microbiom
patient
treat
antibiot
other
steroid
agonist
welldefin
washout
period
antibiot
corticosteroid
use
report
studi
studi
consid
copd
patient
stabl
state
week
laps
last
one
studi
indic
antibiot
use
exacerb
phase
patient
data
avail
dose
corticosteroid
one
studi
report
antibiot
dosag
sinc
mani
studi
use
quantit
approach
quantit
revers
transcriptasepolymeras
chain
reaction
qrtpcr
microbiom
evalu
mandatori
defin
precis
pharmacolog
treatment
washout
durat
antibiot
corticosteroid
suggest
washout
period
antibiot
treatment
least
washout
oral
inhal
corticosteroid
use
consid
evalu
copd
patient
stabl
condit
even
limit
describ
need
studi
larger
sampl
size
welldefin
pharmacolog
treatment
regimen
appear
airway
copd
patient
differ
microbiom
larger
number
bacteria
compar
normal
subject
rather
concord
fact
progress
diseas
reduct
microbi
divers
increas
phyla
proteobacteria
actinobacteria
reduct
other
normal
present
copd
role
bacteri
pathogen
copd
exacerb
recent
investig
exacerb
copd
associ
chang
respiratori
microbiota
airway
inflamm
sethi
et
follow
copd
patient
month
studi
sputum
culturebas
techniqu
stabl
diseas
exacerb
observ
isol
new
strain
pathogen
associ
increas
risk
develop
nonculturebas
techniqu
bacteri
isol
shed
light
role
bacteria
exacerb
process
huang
et
studi
eight
patient
admit
intens
care
unit
copd
exacerb
sampl
obtain
endotrach
aspir
use
nonculturebas
techniqu
qpcr
author
observ
much
greater
divers
bacteria
hitherto
realiz
cultur
techniqu
multipl
oropharyng
gutassoci
bacteri
speci
isol
suggest
potenti
role
strain
copd
exacerb
huang
et
al
hypothes
presenc
two
bacteri
microbiota
relat
exacerb
copd
one
character
preval
proteobacteria
preval
firmicut
might
associ
patient
group
preval
firmicut
shorter
intub
period
perform
endotrach
aspir
moreov
decreas
bacteri
divers
correl
length
specul
antibiot
treatment
could
reduc
bacteri
divers
limit
studi
absenc
control
sampl
nonintub
copd
noncopd
patient
lack
longitudin
dimens
bacteria
oral
caviti
gastrointestin
tract
seed
airway
vulner
patient
millar
et
analyz
pair
sputum
specimen
patient
copd
baselin
exacerb
found
exacerb
associ
select
increas
rel
abund
bacteria
typic
associ
exacerb
eg
haemophilu
pseudomona
moraxella
despit
inconsist
detect
cultur
huang
et
observ
tempor
chang
airway
microbiom
onset
acut
exacerb
studi
bacteri
infect
copd
sputum
sampl
subject
enrol
longitudin
studi
microbiota
member
result
increas
exacerb
mainli
proteobacteria
phylum
treatment
antibiot
alon
decreas
proteobacteria
wherea
treatment
corticosteroid
alon
enrich
proteobacteria
phyla
neither
two
report
decreas
bacteri
commun
divers
would
expect
acut
infect
sever
diseas
better
understand
role
microbiom
exacerb
copd
need
longitudin
studi
exacerb
condit
suffici
extend
stabil
period
includ
appropri
washout
pharmacolog
treatment
well
nontreat
control
parallel
analysi
immunolog
host
respons
associ
differ
clinic
state
copd
patient
also
need
longitudin
conduct
studi
report
grade
sever
exacerb
inde
exacerb
copd
patient
need
chang
medic
home
other
need
admit
intens
care
unit
studi
requir
opinion
address
issu
classifi
exacerb
process
relat
also
sever
bronchial
obstruct
stabl
condit
could
consid
grade
scheme
exacerb
addit
studi
need
character
microbiom
copd
exacerb
list
studi
alreadi
carri
report
tabl
use
pcrbase
approach
amplifi
virusspecif
nucleic
acid
sequenc
document
invas
respiratori
virus
peripher
airway
copd
patient
acut
exacerb
stabl
author
suggest
stabl
copd
viru
colon
could
play
role
maintain
elev
inflammatori
background
utokaparch
et
qpcr
frozen
lung
tissu
gold
stage
copd
patient
stabl
state
healthi
smoker
control
detect
viral
nucleic
acid
patient
two
common
virus
detect
influenza
viru
coronaviru
isol
influenza
viru
preval
copd
patient
control
subject
vs
copd
patient
greater
total
viral
load
greater
number
virus
per
patient
compar
healthi
mallia
et
also
show
signific
invers
relationship
forc
expiratori
volum
secondforc
vital
capac
ratio
number
macrophag
neutrophil
small
airway
direct
relationship
inflammatori
cell
total
viral
load
author
postul
virus
might
act
pathogen
reservoir
copd
copd
patient
consid
suscept
viru
infect
persist
infect
relationship
degre
inflamm
viral
load
need
studi
patient
well
standard
therapeut
condit
corticosteroid
use
could
favor
persist
virus
airway
observ
utokaparch
et
mallia
et
yet
studi
mallia
et
antibiot
cours
exacerb
last
year
enrol
patient
document
specif
inform
antibiot
corticosteroid
use
infrequ
avail
respiratori
viral
infect
tradit
implic
copd
exacerb
rhinoviru
coronaviru
influenza
respiratori
syncyti
virus
parainfluenza
adenoviru
metapneumoviru
virus
often
caus
common
cold
healthi
individu
play
role
acut
exacerb
exacerb
less
sever
less
prolong
recoveri
time
numer
data
onward
show
acut
declin
forc
expiratori
volum
second
copd
patient
day
acut
infect
influenza
recent
demonstr
infect
respiratori
virus
could
influenc
bacteri
microbiom
patient
copd
vice
versa
molyneaux
et
infect
copd
subject
healthi
control
normal
lung
function
rhinoviru
observ
sputum
copd
patient
rise
bacteri
load
signific
preval
h
influenza
respect
exist
microbiota
author
suggest
rhinoviru
infect
copd
alter
respiratori
microbiom
may
induc
secondari
bacteri
infect
parallel
increas
inflammatori
respons
concomit
bacteri
viral
infect
copd
wilkinson
et
observ
copd
exacerb
due
rhinoviru
h
influenza
coinfect
associ
increas
level
serum
compar
exacerb
one
pathogen
isol
similar
find
report
mallia
et
author
observ
copd
patient
experienc
secondari
bacteri
infect
infect
rhinoviru
data
confirm
histolog
analys
infect
lung
sampl
patient
die
type
patient
predomin
caus
death
bacteri
superinfect
result
secondari
bacteri
pneumonia
mice
infect
influenza
viru
increas
suscept
bacteri
respiratori
infect
pneumonia
staphylococcu
aureu
h
influenza
viru
may
caus
suscept
bacteri
superinfect
variou
mechan
damag
epitheli
cell
alter
epithelium
viral
infect
facilit
bacteri
colon
anoth
mode
influenza
viru
favor
bacteri
infect
alter
function
immun
system
result
failur
control
bacteri
replic
figur
influenza
viru
caus
apoptosi
alter
function
alveolar
suppress
activ
respons
secondari
bacteri
challeng
phagocyt
capac
increas
express
cd
receptor
ligat
reduc
express
alveolar
macrophag
scaveng
macrophag
receptor
collagen
structur
marco
macrophag
reduc
product
cytokin
chemokin
alter
respons
cell
pathogen
reduc
exampl
recruit
activ
neutrophil
neutrophil
function
also
alter
influenza
viru
either
direct
infect
induct
type
interferon
secret
lead
inhibit
neutrophil
infiltr
increas
natur
killer
cell
also
affect
influenza
viru
infect
lung
show
reduct
cytotox
activ
product
chemokin
antibacteri
effector
cytokin
tumor
necrosi
evid
induct
highli
polar
type
helper
immun
respons
respiratori
virus
lead
reduct
marco
express
impair
macrophag
abil
ingest
kill
fine
balanc
product
respons
viral
infect
could
explain
excess
suscept
bacteri
superinfect
observ
influenza
viru
van
der
sluij
et
observ
block
product
enhanc
clearanc
secondari
infect
pneumonia
anoth
effect
due
increas
type
interferon
product
follow
influenza
viru
infect
suppress
respons
secondari
bacteri
infect
data
suggest
cell
import
organ
immun
respons
bacteria
pneumonia
aureu
viral
inhibit
pathway
may
form
basi
increas
secondari
bacteri
infect
worst
outcom
copd
patient
interestingli
perera
et
observ
higher
serum
crp
level
copd
patient
day
first
exacerb
episod
correl
shorter
time
next
exacerb
moreov
frequent
exacerb
higher
serum
level
crp
comparison
infrequ
exacerb
author
suggest
higher
inflammatori
indic
frequent
exacerb
could
relat
faster
forc
expiratori
volum
second
declin
increas
mortal
seen
subgroup
nonrespiratori
virus
human
immunodefici
viru
chang
lung
microbiom
facilit
colon
pathogen
gastrointestin
bacteria
infect
rel
data
avail
concern
viral
infect
copd
patient
caus
influenza
viru
coronaviru
respiratori
syncyti
viru
among
nonrespiratori
virus
involv
copd
exacerb
lung
microbiom
alter
data
limit
human
immunodefici
viru
moreov
studi
includ
patient
mild
consequ
studi
investig
host
immun
respons
relat
differ
stage
phenotyp
copd
patient
need
specif
data
viral
bacteri
infect
stabl
exacerb
copd
relat
host
immun
respons
need
produc
gain
clearer
pictur
interrelationship
relat
immun
process
copd
copd
ill
character
abnorm
inflammatori
respons
lung
inflammatori
cell
infiltr
airway
patient
vari
accord
stage
diseas
recent
find
show
immun
respons
impair
copd
microbiom
airway
copd
patient
alter
increas
diseas
sever
exacerb
process
alter
normal
bacteri
popul
copd
patient
reduct
bacteri
varieti
associ
increas
risk
exacerb
sever
bacteria
virus
play
pivot
causal
role
copd
exacerb
diseas
progress
stabl
copd
patient
harbor
respiratori
virus
airway
bacteria
virus
lung
could
play
role
maintain
inflammatori
state
copd
patient
stabl
phase
evid
bacteri
viral
load
airway
stabl
copd
directli
correl
airway
inflamm
studi
evid
bacteri
phyla
proteobacteria
capabl
stimul
inflamm
airway
copd
patient
date
still
clear
bacteria
influenc
inflammatori
respons
lung
lung
viru
infectioncolon
alter
local
microbiom
word
dynam
process
involv
bacteri
viral
challeng
abl
chang
clinic
statu
patient
relat
host
innat
adapt
immun
respons
need
better
explor
genet
chang
probabl
present
copd
differ
stage
sever
vs
mild
differ
phenotyp
frequent
exacerb
vs
nonfrequ
outsid
scope
present
review
wellplan
studi
appli
appropri
washout
period
therapeut
treatment
copd
patient
differ
clinic
condit
also
need
correct
quantit
microbiom
differ
clinic
state
understand
dynam
lung
microbiom
differ
clinic
condit
interact
relat
endogen
host
immun
respons
improv
knowledg
patholog
molecular
mechan
underli
copd
consequ
enabl
develop
new
therapeut
strategi
limit
progress
diseas
